BiotechTube

Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic Solution

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergic Conjunctivitis

Conditions

Allergic Conjunctivitis

Trial Timeline

Mar 30, 2018 → Nov 5, 2018

NCT ID
NCT03494504

About Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic Solution

Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic Solution is a phase 3 stage product being developed by Aldeyra Therapeutics for Allergic Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03494504. Target conditions include Allergic Conjunctivitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT03709121Phase 1/2Completed
NCT03660878Phase 1/2Completed
NCT03494504Phase 3Completed

Competing Products

20 competing products in Allergic Conjunctivitis

See all competitors
ProductCompanyStageHype Score
BriquilimabJasper TherapeuticsPhase 1
25
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
77
Lesigercept + PlaceboYuhanPhase 2
52
YH35324 + Omalizumab + PlaceboYuhanPhase 1
33
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP2390 + PlaceboAstellas PharmaPhase 1
33
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Prednisolone + VoriconazoleCiplaPhase 2/3
65
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
85
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
33
ciclesonide + mometasoneSumitomo PharmaPhase 3
77
DSP-3025 + PlaceboSumitomo PharmaPhase 1
33
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
77

Other Products from Aldeyra Therapeutics

Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BIDPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
ADX-2191 (intravitreal methotrexate 0.8%)Phase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Placebo Comparator + Reproxalap Ophthalmic Solution (0.25%) + Placebo ComparatorPhase 3
69